In patients with AD, several studies have demonstrated an increase in Total Tau (T-Tau), phosphorylated Tau (pTau), and neurofilament light levels in cerebral spinal fluid (CSF), and a decrease in CSF Aβ1–42 [83]. This evidence concerns the gene MAPT and Alzheimer disease.